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S U M M A R Y
Objective: To estimate HIV incidence among female sex workers (FSWs) by serial cross-sectional surveys
and IgG-capture BED-enzyme immunoassay (BED-CEIA).
Methods: We conducted three cross-sectional surveys, 6 months apart, among all consenting FSWs in
Kaiyuan City, China. HIV antibody-positive samples were also tested by BED-CEIA.
Results: Among 1412 unique participants, 475 tested HIV-negative and attended >1 survey
(longitudinal cohort). Compared to 786 HIV-negative FSWs who only participated once, the longitudinal
cohort reportedmore illicit drug use (10.9% vs. 7.4%, p = 0.03), injected drugsmore often in the previous 3
months (8.8% vs. 5.3%, p = 0.02), and hadmore positive urine opiate tests (13.7% vs. 8.9%, p = 0.008). Four
participants in the longitudinal cohort seroconverted over the year, with an overall incidence of 1.1/100
person-years (95% conﬁdence interval (CI) 0.3–2.8). Crude BED-CEIA incidencewas 3.4/100 person-years
(95% CI 2.3–4.4) with adjusted rates similar to the cohort incidence: McDougal, 1.5/100 person-years
(95% CI 1.0–2.0); Hargrove, 1.6/100 person-years (95% CI 1.1–2.1). The BED-CEIA false-positive rate was
4.4% (10/229) among samples from FSWs known to be infected 365 days.
Conclusions: Although limited by power, this study provides additional data towards validating BED-
CEIA in China. If conﬁrmed by other studies, BED-CEIA will be a useful tool to estimate HIV incidence
rates and trends.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Understanding the incidence of HIV infection in a population is
critically important to understand the dynamics of HIV transmis-
sion. Prospective cohort studies are often used to determine disease
incidence but are difﬁcult to conduct well because of the associated
time, effort, and expense required. Biases can also be introduced if
thecohort recruited isnot representativeof the largerpopulation.An
alternative method to estimate HIV incidence is the IgG-capture
BED-enzyme immunoassay (BED-CEIA),1 which can distinguish
recent infection from longer-term infection by measuring the* Corresponding author at: National Center for AIDS/STDs Control and Preven-
tion, Chinese Center for Disease Control and Prevention, 27 Nanwei Road, Xuanwu
District, Beijing 10050, PR China. Tel.: +86 10 6303 9093; fax: +86 10 6303 9093.
** Co-corresponding author.
E-mail addresses: hongshang100@hotmail.com (H. Shang), wangnbj@163.com
(N. Wang).
1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.09.004proportion of HIV-IgG to total IgG after HIV-1 seroconversion. With
this assay, HIV incidence can be estimated using cross-sectional
surveys.2,3 TheperformanceofBED-CEIA for recentHIV infectionhas
been validated inNorthAmerica and theNetherlands (subtypeB),4,5
Thailand (subtypes B and E),1,6,7 Zimbabwe (subtype C),8 and Kenya
(subtypesA,D, andC).1 Other validation studies inAfrican countries,
however, have found thatBED-CEIAoverestimatedHIV incidenceby
2–4-fold compared to prospective studies or models.9–12 Accord-
ingly, the Joint United Nations Programme on HIV/AIDS (UNAIDS)
has warned that BED-CEIA-related misclassiﬁcation may be
particularly severe in areas with high HIV prevalence and that
estimates may vary by HIV-1 subtype.11 The US Centers for Disease
Control and Prevention (CDC) recommend the two formulas of
McDougal4 andHargrove8 to correct themisclassiﬁcation.However,
the two adjusted formulas have only had limited validation using
HIV subtypes A1, B, and C.12,13
In China, where the predominant HIV subtypes are circulating
recombinant forms of subtypes B and C (CRF_BC),14 previousses. Published by Elsevier Ltd. All rights reserved.
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sectional and did not account for subtype.15–17 The objectives of
this study were to determine HIV incidence among female sex
workers (FSW) in Kaiyuan City, China, through a longitudinal
cohort derived from serial cross-sectional surveys, and to compare
this cohort study-derived incidence with the BED-CEIA estimated
incidence, while accounting for HIV subtype.
2. Methods
2.1. Study design
ThisstudywasconductedinKaiyuanCity,YunnanProvince,China
as three serial cross-sectional surveys, 6 months apart, between
March 2006 and April 2007. A general census designwas adopted in
each of the three cross-sectional surveys. All available community-
based FSWs from local entertainment venues were recruited to the
study site by outreach workers, with those meeting the following
inclusion criteria enrolled: (1) worked in Kaiyuan entertainment
venues; (2) women 16 years old; and (3) self-reporting receiving
money for sex within the previous 3 months. Participants failing to
meet any one of these inclusion criteria were excluded. For this
analysis, the baseline characteristics of all initially HIV-negative
participants attendingmore thanone surveywere compared against
HIV-negative participants who attended only one survey.
After providing informed consent and HIV pre-testing counsel-
ing, participants were administered an anonymous questionnaire
by trained interviewers. The questionnaire included questions
about demography, sexual behavior, drug use experience, condom
using behavior with male clients, and vaginal douching behavior.
2.2. HIV antibody and BED-CEIA testing
Blood samples were collected and tested for HIV antibody by
ELISA (Organon Teknika, Boxtel, Co., Ltd, the Netherlands). All
positive samples were conﬁrmed by Western blot (HIV Blot 2.2
WB; Genelabs Diagnostics, Singapore) and tested for HIV subtype.
All Western blot-positive samples, including those previously
testing positive, were also tested by BED-CEIA (Calypte Biomedical
Corporation, Rockville, MD, USA). Specimens with initial ODn 1.2
were tested in triplicate to conﬁrm their ODn values. If the median
ODn value from all three tests was <0.8, the specimen was
considered recently infected (155 days), otherwise, the specimen
was classiﬁed as chronic infection.
2.3. Sequence analysis
HIV RNA was extracted by QIAamp Viral RNA Mini Kit (Qiagen
Inc., Hilden, Germany) according to themanufacturer’s instructions,
and resuspended with RNA diluent. The nucleotide sequences of
2.6 kb gag-RT and C2V3 of env were determined from viral RNA.18
The nested-PCR product was puriﬁed with the QIAquick Gel
Extraction Kit and sequenced with the ABI3100 DNA Sequencer
(AppliedBiosystems Inc.). Sequence fragmentswere linkedbyContig
Express program of Vector NTI Advance 10 (Invitrogen, USA). The
sequences were aligned with previously reported HIV-1 strains of
various subtypes fromthe LosAlamosdatabase.Multiple alignments
wereperformedbyCLUSTALWwithminormanual adjustments.The
Kimura 2-parameter method was used for the determination of the
evolutionary distance. The reliability of the branching patterns was
assessed by bootstrap analysiswith 500 replicates. Phylogenetic and
molecular evolutionary analyses were conducted using MEGA
version 3.1 (Molecular Evolutionary Genetics Analysis, Tempe, AZ,
USA). Simplot version3.2wasused to identify recombination strains.
The bootstrap valueswere plotted for awindowof 200 bpmoving in
increments of 50 bp along the alignment.2.4. Data management and statistical analysis
The crude BED-CEIA estimated HIV incidence was calculated
using the US CDC recommended formula: I = 100  [(365/
w)  Ninc]/[Nneg + (365/w)  (Ninc/2)],13 in which w is the window
period (155 days), Ninc is the number of recent HIV infections as
determined by BED-CEIA, and Nneg is the total number of HIV-
seronegative subjects. The 95% conﬁdence intervals (CI) for
estimated BED-CEIA incidence were calculated by: 95%
CI = I  1.96(I/HNinc).13 Subjects who tested BED-CEIA-positive but
were documented by local CDC records (before the baseline survey) or
previous study records (from the baseline survey) already to be HIV-
positive at least 365 days before (about twice the BED-CEIA window
period) were deﬁned as false-positives (also referred to as mis-
classiﬁcations) and were excluded from the calculation of HIV
incidence.19 The crude HIV incidence as determined by BED-CEIAwas
then adjusted using the US CDC recommended formulas of McDougal
and Hargrove.13 Exact 95% CI were calculated for HIV incidence based
on the Poisson distribution. Comparisons of high-risk behaviors
between groups were performed by Chi-square test, independent t-
test or Wilcoxon rank sum test. SAS 9.1 (SAS Institute Inc., Cary, NC,
USA) was used for data analysis. The questionnaires and study
protocol were approved by the institutional review boards of the
China CDC and Yunnan CDC.
3. Results
3.1. Baseline characteristics of FSW participants
The three cross-sectional surveys conducted included 737, 747,
and 705 FSWs, respectively, and of these, there were 1412 unique
participants. Among the participants, 151 initially tested HIV-
positive, with 68 (45.0%) returning for a second or third survey.
Among the remaining 1261 initially HIV-negative FSWs, 475
participated in more than one survey and were included in the
longitudinal cohort (236 FSWs attended all three surveys). These
were compared with the 786 HIV-negative FSWs who only
participated in one survey (Table 1). FSWs who returned for more
than one visit were signiﬁcantly older at baseline (26.2 vs. 24.4
years, p < 0.001), older when they ﬁrst engaged in commercial sex
(23.5 vs. 22.5 years, p = 0.002), self-reported more use of illicit
drugs (10.9% vs. 7.4%, p = 0.03), injected drugs more often in the
previous 3 months (8.8% vs. 5.3%, p = 0.02), and had more positive
urine opiate tests in the study (13.7% vs. 8.9%, p = 0.008).
3.2. Incidence of HIV by longitudinal cohort study
At the 6-month survey, two FSWs were found to have
seroconverted in the longitudinal cohort. At the 12-month survey,
two more FSWs seroconverted, one of whom seroconverted
between the 6- and 12-month surveys and the other between
the initial and 12-month surveys (she did not participate in the 6-
month survey). The overall HIV incidence rate for the year was 1.1/
100 person-years (95% CI 0.3–2.8; Table 2). The four HIV incident
FSWs had a median age of 31.7 years. All had received less than 9
years of formal education. By self-report, only one of the four was
an injection drug user (IDU). The four HIV incident FSWs reported a
daily average of 2.5 clients (ranging from two to four clients) and a
weekly average of 14.5 clients. One of the four FSWs had not used a
condomwith hermost recent client and three of the four had failed
to use a condom with at least one client in the previous week.
3.3. HIV incidence as measured by BED-CEIA assay
In the three cross-sectional surveys, all HIV antibody-positive
specimenswere tested by BED-CEIA,with 7/76, 15/89, and 16/92 of
Table 1
Baseline high-risk behaviors comparison between female sex workers initially testing HIV-negative who were included or not included in the longitudinal cohort in Kaiyuan
City, China, 2006–2007.
Variable Included in longitudinal cohort- (n=475) Not included in longitudinal cohorta (n=786) p-Value
Mean age (years) 26.26.8 24.46.1 <0.001
Han nationality (%) 319 (67.2) 537 (68.3) 0.67
Mean schooling years 7.23.2 7.13.3 0.49
Mean age at ﬁrst intercourse (years) 18.42.3 18.22.2 0.062
Mean age at ﬁrst commercial sex (years) 23.56.0 22.55.4 0.002
Self-reported drug use history (%) 52 (10.9) 58 (7.4) 0.030
Injected drugs in previous 3 months (%) 42 (8.8) 42 (5.3) 0.016
Positive urine opiate test (%) 65 (13.7) 70 (8.9) 0.008
Self-reports vaginal douching (%) 385 (81.1) 596 (75.8) 0.031
Median number of clients in previous week (IQR) 3 (2–5) 3 (2–7) 0.002
Consistent condoms with clients in previous week (%) 407 (85.7) 659 (83.8) 0.38
Condom using rate with the last client (%) 439 (92.4) 713 (90.7) 0.30
IQR, interquartile range. Variables are described as mean standard deviation, median (IQR), or rate. Statistical comparisons between groups were carried out by t-test or
Wilcoxon rank test for continuous variables and Chi-square test for categorical variables.
a Longitudinal cohort members are deﬁned as those participants who attended more than one visit; subjects not included in the longitudinal cohort are deﬁned as those
attending one visit only.
Table 2
BED-CEIA and longitudinal cohort study derived incidence of HIV among female sex workers in Kaiyuan City, China, 2006–2007
Variable Survey stages
Baseline survey 6-month survey 12-month survey Total
Total FSWs 737 747 705 1412
Number of HIV-positives among total FSWs 76 89 92 155
Returned FSWs - 299 330 475
Number of HIV-positives among returned FSWs - 42 60 68
Seroconverted FSWs in the cohort - 2 2 4
Cohort derived IHIV+, /100 PY (95% CI) - 1.3 (0.2–4.7) 0.6 (0.1–2.0) 1.1 (0.3–2.8)
BED tested long-term infection 69 74 76 219
BED tested recent infection 7 15 16 38
BED false-positive for recent infection 1 3 6 10
Crude IHIV+, /100 PY (95% CI) 2.1 (0.6–3.7) 4.2 (2.1–6.3) 3.8 (1.9–5.6) 3.4 (2.3–4.4)
Adjusted IHIV+, /100 PY (95% CI)
a 0.4 (0.1–0.7) 2.4 (1.2–3.6) 1.7 (0.9–2.5) 1.5 (1.0–2.0)
Adjusted IHIV+, /100 PY (95% CI)
b 0.4 (0.1–0.8) 2.6 (1.3–3.9) 1.8 (0.9–2.7) 1.6 (1.1–2.1)
BED-CEIA, IgG-capture BED-enzyme immunoassay; FSW, female sex workers; IHIV+, HIV incidence; PY, person-years; CI, conﬁdence interval.
a Sensitivity/speciﬁcity adjustment by McDougal suggested formula.
b Speciﬁcity adjustment by Hargrove suggested formula.
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these, 1/7 (14.3%), 3/15 (20.0%), and 6/16 (37.5%) had a
documented HIV-positive result at least 365 days before (either
through records from the local CDC or in this study), giving an
overall false-positive misclassiﬁcation ratio of 26.3% (10/38;
Table 2) among those testing positive for recent infection. Among
the total 257 HIV-positive samples, 229 were known to have been
infected for longer than 365 days. Of these, 16 tested BED-CEIA-
positive for a false-positive misclassiﬁcation rate of 4.4% (10/229).
Of the nine FSWs taking antiretrovirals during the surveys, none
tested BED-CEIA-positive.
The overall annualized crude incidence of HIV by BED-CEIA was
3.4/100 person-years (95% CI 2.3–4.4), which was more than three
times the total incidence by cohort study (1.1/100 person-years,
95% CI 0.3–2.8; Table 2), but with overlapping 95% conﬁdence
intervals. The overall adjusted incidence of HIV (McDougal, 1.5/100
person-years (95% CI 1.0–2.0); Hargrove, 1.6/100 person-years
(95% CI 1.1–2.1)) was similar to the total incidence by longitudinal
cohort study (1.1/100 person-years (95% CI 0.3–2.8)), also with
overlapping 95% conﬁdence intervals (Table 2).
3.4. Detection of seroconverted specimens by BED-CEIA testing
Among the four seroconverters in the study, the two who
converted between the baseline and 6-month surveys (within 180
days) tested BED-CEIA-positive for recent infection at the 6-month
survey but negative for recent infection at the 12-month survey.The participant who converted between the 6- and 12-month
surveys tested BED-CEIA-positive for recent infection at the 12-
month survey. The participant who converted between the
baseline and 12-month survey tested BED-CEIA-negative for
recent infection at the 12-month visit.
3.5. Distribution of HIV subtypes among FSW participants
We were able to subtype 113 (72.9%) of the total 155 HIV-
positive samples collected from unique FSWs. Of these, 74 (65.5%)
were CRF_08BC; 16 (14.2%) were CRF_07BC; 12 (10.6%) were
subtype C; 10 (8.9%) were unclassiﬁable recombinant strains, and
one (0.9%) was CRF_01AE. None of the 10 unclassiﬁable recombi-
nant strains were classiﬁed as false-positive recent infections by
BED-CEIA. Of the samples from the four seroconverters, two were
successfully subtyped (CRF_08BC and C). Among the 10 FSWs who
had false-positive BED-CEIA results, we were able to identify the
virus subtype for eight: ﬁve were CRF_08BC, two were CRF_07BC,
and one was subtype C. This distribution was not signiﬁcantly
different from the overall distribution (p = 0.84).
4. Discussion
The primary purpose of this study was to validate the BED-CEIA
method to estimate HIV incidence in a cohort of FSWs in Kaiyuan
City, Yunnan Province, China. We adopted a general census design
among FSWs at the three cross-sectional surveys, recruiting about
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local CDC, there were about 800 FSWs working in Kaiyuan City), in
an effort to decrease selection bias. By using 475 initially HIV-
negative FSWs who participated in at least two of three cross-
sectional surveys 6months apart, we found the cohort-derived HIV
incidence was 1.1/100 person-years (95% CI 0.3–2.8), which was
similar to the McDougal-adjusted (1.5/100 person-years (95% CI
1.0–2.0)) and Hargrove-adjusted (1.6/100 person-years (95% CI
1.1–2.1)) HIV-incidences. Of note, although the crude BED-CEIA
calculated annualized incidence (3.4/100 person-years (95% CI
2.3–4.4)) was more than three-fold higher than the cohort
incidence, this difference was not statistically signiﬁcant. HIV
subtypeswere also determined, but our numberswere too small to
make any deﬁnitive correlations between the subtypes identiﬁed
and BED-CEIA misclassiﬁcation.
Many studies have already validated the relationship between
BED-CEIA estimated HIV incidence and cohort study derived HIV
incidence.1,7,8 In China, studies have used BED-CEIA to estimate
crude HIV incidence among IDUs in retrospective, cross-sectional
analyses.15,16 Another cross-sectional BED-CEIA study found similar
HIV incidence rates as the cohort study conducted concurrently in
the same population.17 Our study, the ﬁrst in China to evaluate the
BED-CEIA method by direct comparison with a cohort-identiﬁed
incidence rate in the same subjects, conﬁrms that the adjusted BED-
CEIA rates are comparable to our cohort-identiﬁed rate. Although
the crude BED-CEIA ratewas also not statistically different from our
cohort incidence rate despite being over three-fold higher, this was
likelydue to the lownumberofHIV seroconversions identiﬁed inour
cohort and the subsequent lack of sufﬁcient power to discriminate
between the two results.Ourprevious study inKaiyuan identiﬁedan
HIV prevalence of 10% overall among the FSWs and 30% among the
drug-using FSWs.20We thus expected to ﬁndmore seroconversions
during this one-year study. Furthermore, based on the demo-
graphics of the FSWs included in our longitudinal cohort, it appears
that these FSWs had greater risk for acquiring HIV infection due to
being older and having signiﬁcantly more drug use compared to
those not included in our cohort (Table 1). Despite this, it is possible
that our longitudinal cohort was biased andmissed the highest risk
FSWs in the area.
Among subjects known to be infected for more than 365 days,
our study identiﬁed a false-positive misclassiﬁcation rate of 4.4%
(10/229), identical to the previously reported proportion in
China.17 However, among the smaller group of subjects testing
positive for recent HIV infection, the false-positive misclassiﬁca-
tion ratio was 26.3% (10/38).We did not ﬁnd a correlation between
HIV subtype and misclassiﬁcation, but our results are limited by
the small sample size. Additional validation studies in China with
larger sample sizes are needed to determine the misclassiﬁcation
rate more accurately and its potential correlation with HIV
subtype. These data are needed to know how to interpret correctly
future cross-sectional BED-CEIA results at the population level,
where prior testing results are not available or have not been
obtained.
All three subjects who seroconverted within 180 days had BED-
CEIA results demonstrating recent infection. Two of these subjects
subsequently participated in the third survey and were correctly
identiﬁed by BED-CEIA as subjects with long-term infection. The
fourth subject, who seroconverted within 365 days, had a BED-
CEIA result showing long-term infection. On the other hand, the
BED-CEIA test misclassiﬁed 10/38 (26.3%) of samples, classifying
subjects with long-term infections as having recent infections. This
rate of misclassiﬁcation is less than that reported in Zimbabwe
(37.8%, 142/376).8
Antiretroviral therapy has also been associated with BED-CEIA
misclassiﬁcation,21 but did not play a role in our study, with all nine
FSWswhowere on treatment in our study correctly testing negativeby BED-CEIA. Moreover, the storage, shipment, and testing
procedures were conducted by US CDC recommended standards,
so these factors should not affect the results signiﬁcantly.13
The primary limitation of our study is the relatively small
sample size. Because the numbers of FSWs who seroconverted
fromHIV-negative to -positivewere small, our 95% CI for incidence
were relatively large, preventing us from identifying statistically
signiﬁcant differences between the crude and adjusted BED-CEIA
incidence rates and our cohort-derived incidence rate. Second, our
low retention rate may have biased our cohort study-derived HIV
incidence, as the highest risk subjects may not have returned for
subsequent testing. Our data indicate, however, that the subjects
included in our longitudinal cohort actually had higher rates of
drug use than those not included (Table 1) making this selection
bias less likely. Third, this study provided voluntary HIV counseling
and testing (VCT) to each FSWparticipant during the survey, which
may have partly resulted in decreased HIV-related behaviors,
resulting in lower numbers of new HIV infections. From this
perspective, our cohort-derived incidence may underestimate the
true incidence. Finally, all BED-CEIA related parameters, such as
the window period (155 days) and conﬁrmatory ODn value (0.8),
were adapted from the US CDC’s recommendations. These values
may or may not be the same for Chinese HIV subtypes and may
need to be adjusted. Further studies in China are needed to
understand these issues.
In conclusion, this study provides additional data towards
validating the use of the BED-CEIA assay to estimate HIV incidence
rates in China, with adjusted BED-CEIA rates similar to the cohort-
derived incidence. Differentiation between the cohort-derived and
the crude BED-CEIA incidence rates, as well as the correlation
betweenHIV subtypes and BED-CEIAmisclassiﬁcation, was limited
by insufﬁcient power. Additional studies with larger sample sizes
are needed to evaluate more precisely how well BED-CEIA
estimates HIV-incidence and incidence trends in Chinese popula-
tions. Should these studies conﬁrmour outcomes, BED-CEIAwill be
a useful and inexpensive tool for HIV surveillance and intervention
evaluations in China.
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